for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Achieve Life Sciences Inc

ACHV.OQ

Latest Trade

0.88USD

Change

0.18(+25.86%)

Volume

630,846

Today's Range

0.70

 - 

0.93

52 Week Range

0.66

 - 

4.61

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.70
Open
0.83
Volume
630,846
3M AVG Volume
5.08
Today's High
0.93
Today's Low
0.70
52 Week High
4.61
52 Week Low
0.66
Shares Out (MIL)
8.35
Market Cap (MIL)
5.85
Forward P/E
-0.41
Dividend (Yield %)
--

Next Event

Q4 2019 Achieve Life Sciences Inc Earnings Release

Latest Developments

More

Achieve Life Sciences Says Co Completed Meeting With U.S. FDA On Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

Achieve Life Sciences Files For Offering Of 4.3 Million Class A Units & 16,014 Class B Units - SEC Filing

Achieve Life Sciences Inc - QTRLY Diluted Net Loss Per Share $0.45

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Achieve Life Sciences Inc

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.

Industry

Biotechnology & Drugs

Contact Info

520 Pike St Ste 2250

+1.425.6861500

http://achievelifesciences.com/

Executive Leadership

Richard Stewart

Chairman of the Board, Chief Executive Officer

Anthony Clarke

President, Chief Scientific Officer, Director

John A. Bencich

Chief Financial Officer, Chief Operating Officer, Executive Vice President

Cindy Jacobs

Executive Vice President, Chief Medical Officer

Scott Daniel Cormack

Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-3.610

2019(E)

-1.720
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.04
LT Debt To Equity (MRQ)
2.60
Return on Investment (TTM)
-149.46
Return on Equity (TTM)
-117.61

Latest News

Latest News

BRIEF-Achieve Qtrly Basic And Diluted Net Loss Per Share $0.24

* QTRLY BASIC AND DILUTED NET LOSS PER SHARE $0.24 Source text for Eikon: Further company coverage:

BRIEF-Achieve Announces Patent Granted On Novel Formulation Of Cytisine

* ACHIEVE ANNOUNCES PATENT GRANTED ON NOVEL FORMULATION OF CYTISINE Source text for Eikon: Further company coverage:

BRIEF-Achieve Life Sciences Inc Qtrly Loss Per Share ‍$0.32​

* ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE $0.32 Source text for Eikon: Further company coverage:

BRIEF-Achieve qtrly loss per share $0.90

* Achieve Life Sciences Inc qtrly loss per share $0.90 Source text for Eikon: Further company coverage:

BRIEF-Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD

* Achieve Life Sciences - co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets

BRIEF-ACHIEVE LIFE SCIENCES COMMENCES ADVANCEMENT OF CYTISINE CLINICAL DEVELOPMENT PROGRAM

* ACHIEVE LIFE SCIENCES INC - ANNOUNCES COMMENCEMENT OF A MULTI-DOSE STUDY TO EVALUATE BOTH PK AND PD CHARACTERISTICS OF CYTISINE

BRIEF-Achieve announces share purchase agreement with Lincoln Park Capital Fund

* Achieve announces share purchase agreement with Lincoln Park Capital Fund LLC

BRIEF-Achieve Life Sciences ‍announces initiation of Cytisine clinical development program​

* Achieve Life Sciences Inc - Announced initiation of Cytisine clinical development program

BRIEF-Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences as of Aug 1

* Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences Inc as of August 1, 2017 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-FDA accepts Achieve's IND for its smoking cessation drug

* Achieve announces FDA acceptance of the investigational new drug application (IND) for cytisine as a smoking cessation treatment

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up